Geriatric urology - Tumour diseases;Geriatrische urologie - Tumorerkrankungen

Aktuelle Urologie

Volumn 37, Issue 1, 2006, Pages 45-51

  Krege, S ^a   Friedrich, C ^a   Pientka, L ^a   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Co morbidities; Geriatric oncology; Perioperative management; Systemic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; TAXOID;

AGED; BLADDER TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT CARE; PROSTATE TUMOR; REVIEW; UROGENITAL TRACT TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PROSTATIC NEOPLASMS; TAXOIDS; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 33644514605     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-919101     Document Type: Review

References (61)

1. Katz S, Branch LG, Branson MH, Papsidero JA, Beck JC, Greer DS. Active life expectancy. N Engl J Med 1983; 309: 1218-1224
2. Yancik R, Havlik RJ et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996; 6: 399-412
3. Coebergh JW, Janssen-Heijnen ML et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993-1996. J Clin Epidemiol 1999; 52: 1131-1136
4. Albertsen PC, Fryback DG et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127-132
5. Welch HG, Albertsen PC et al. Assessing competing risks in treating the elderly. Hosp Pract (Off Ed) 1996; 31: 155-156, 158-159, 162, passim
6. Newschaffer CJ, Bush TL et al. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol Biol Sci Med Sci 1996; 53: 372-378
7. Kattan MW, Cowen ME et al. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997; 12: 299-305
8. Barry MJ, Albertsen PC, Bagshaw MA et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302-2314
9. Froehner M, Koch FR, Litz R et al. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 2003; 62: 698-701
10. Froehner M, Koch R, Litz R et al. Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 2004; 171: 97-699
11. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453-471
12. Wolters U, Wolf T, Stutzer H. ASA classifications and perioperative variables as predictors of postoperative outcome. Br J Anesth 1996; 77: 217-222
13. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
14. Greenfield S, Blanco DM et al. Patterns of care related to age of breast cancer patients. J Am Med Assoc 1987; 257: 2766-2770
15. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404
16. Cohen HJ. Cancer and the functional status of the elderly. Cancer 1997; 80: 1883-1886
17. Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur J Cancer 1999; 35: 1771-1772
18. Serraino D, Fratino L, Zagonel V. Prevalence of functional disability among elderly patients with cancer. Crit Rev Oncol Hematol 2001; 39: 269-273
19. Krege S, Friedrich C et al. Geriatrisches Assessment: Sinnvolle Hilfe bei der Auswahl älterer Tumorpatienten für eine belastende Therapie? Urol A 2004; 43: 922-929
20. Friedrich C, Pientka L, Kolb G et al. Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 2003; 26: 355-360
21. Thomas DM, Riddle PR. Morbidity and mortality in 100 consecutive radical cystectomies. Br J Urol 1982; 54: 716-719
22. Rosario DJ, Becker M, Anderson JB. The changing pattern of mortality and morbidity from radical cystectomy. Br J Urol 2000; 85: 427-430
23. Peyromaure M, Guerin F, Debre B, Zerbib M. Surgical management of infiltrating bladder cancer in elderly patients. Eur Urol 2004; 45: 147-154
24. Figueroa A, Stein JP, Dickinson M et al. Radical cystectomy for elderly patients with bladder carcinoma. Cancer 1998; 83: 141-147
25. Chang SS, Alberts G, Cookson MS, Smith JA. Radical cystectomy is safe in elderly patients at high risk. J Urol 2001; 166: 938-941
26. Lance RS, Dinney CP, Swanson D et al. Radical cystectomy for invasive cancer in the octogenarian. Oncol Rep 2001; 8: 723-726
27. Stroumbakis N, Herr HW, Cookson MS, Fair WR. Radical cystectomy in the octogenarian. J Urol 1997; 158: 2113-2117
28. Game' X, Soulie M, Seguin P et al. Radical cystectomy in patients older than 75 years: Assessment of morbidity and mortality. Eur Urol 2001; 39: 525-529
29. Frazier HA, Robertson JE, Paulson DF. Complication of radical cystectomy and urinary diversion: a retrospective study of 675 cases in 2 decades. J Urol 1992; 148: 1401-1404
30. Hautmann RE, Petriconi R de, Gottfried HW et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999; 61: 422-427
31. Stein JP, Liesskowsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1054 patients. J Clin Oncol 2001; 19: 666-675
32. Leibovitch I, Avigad I, Ben-Chaim J et al. Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder? Cancer 1993; 71: 3098-3101
33. Takashi S, Bunzo S, Tadashi M et al. Orthotopic neobladder reconstruction in elderly bladder cancer patients. Int J Urol 2001; 8: 533-538
34. Gschwend JE, Hautmann RE, Volkmer BG. Radikale Zystektomie und Harnableitung beim älteren Patienten mit erhöhter Komorbidität. Urol A 2004; 43: 930-934
35. Clark PE, Stein JP, Groshen SG et al. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer 2005; 103: 546-552
36. Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76-84
37. Lindemann RD. Overview: renal physiology and pathophysiology of aging. Am J Kidney Diss 1990; 16: 275-282
38. Enright PL. Aging of the Respiratory System. In: Hazzard WR et al. (eds.) Principles of Geriatric Medicine & Gerontology. New York: McGraw-Hill, 2003: 511-515
39. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol 1995; 22: 9-10
40. Balducci L, Hardy CL, Lyman GH. Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol 2001; 8: 170-187
41. Bokemeyer C, Honecker F, Wedding U et al. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie 2002; 25, 1: 32-39
42. Lichtman SM, Skirvin JA, Vernulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 2003; 46, 2: 101-114
43. Wit R de. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. Eur J Cancer 2005; 41: 502-507
44. Tannock IF, Wit R de, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351, 15: 1502-1512
45. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and extramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351, 15: 1513-1520
46. Abratt RP, Brune D, Dimopoulos MA et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004; 15: 1613-1621
47. Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an Oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2-9
48. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade? Eur J Cancer 2005; 41: 941-953
49. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology 2005; 65: (Suppl 5A): 9-17
50. Bamias A, Efstathiou E, Moulopoulos LA. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncology 2005; 16: 307-313
51. Fossa SD, Sternberg C, Scher HI et al. Survival of patient with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996; 74: 1655-1659
52. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181
53. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality of life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 2003; 21: 673-678
54. Millikan R, Dinney C, Swanson D et al. (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomised trial of cystectomy plus adjuvant MVAC versus cystectomy with both preoperative and postoperative MVAC. J Clin Oncol 2003; 19: 4005-4013
55. Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003; 97: 2180-2186
56. Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction: a trial of the Eastern Co-operative Oncology Group. Cancer 2002; 95: 1022-1027
57. Hussain M, Vaishampayan U, Du W et al. Combination carboplatin, paclitaxel and gemcitabine is an active treatment for advanced urothelial carcinoma. J Clin Oncol 2001; 19: 2527-2533
58. Castagneto B, Zai S, Marenco D et al. Single agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 2004; 67: 27-32
59. Aparicio AM, Elkhouiery AB, Quinn DI. The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. Urol Clin N Am 2005; 32: 217-230
60. Coffin JR, Rajan R, Souhami L. Tolerance of radiotherapy and chemotherapy in elderly patients with Bladder cancer. Am J Clin Oncol 2004; 27: 172-177
61. Post P, Kil P, Hendrikx A et al. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 1999; 84: 652-656